Targeting FGFR: Urothelial Cancer and Beyond (Podcast Pearls)

Experts, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss the most recent clinical data on targeting FGFR in urothelial cancer and beyond.
Alison Birtle, MD, FRCP, FRCR
Ignacio Duran, MD, PhD
Format: Adobe Acrobat (.pdf)
File Size: 122 KB
Released: April 1, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Janssen Pharmaceutica NV

Related Content

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 28, 2022

Data on dostarlimab for locally advanced, mismatch repair-deficient rectal cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

Expanded results from CheckMate 648 of first-line nivolumab + chemotherapy or ipilimumab vs chemotherapy alone in advanced esophageal squamous cell cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 13, 2022

CAIRO5: FOLFOXIRI + bevacizumab vs FOLFOX/FOLFIRI + bevacizumab in initially unresectable colorectal liver metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings